1 / 29

EUCAST Chairman´s report to the ESCMID February 28, 2003

EUCAST Chairman´s report to the ESCMID February 28, 2003. Gunnar Kahlmeter Chairman 2002 – 2004. EUCAST. ESCMID board EUCAST general committe EUCAST steering committe. Austria Prof Helmut Mittermayer Belgium Prof Jan Verhaegen Bosnia Dr Selma Uzunovic-Kamberovic

cais
Télécharger la présentation

EUCAST Chairman´s report to the ESCMID February 28, 2003

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EUCASTChairman´s report to the ESCMID February 28, 2003 Gunnar Kahlmeter Chairman 2002 – 2004

  2. EUCAST ESCMID board EUCAST general committe EUCAST steering committe

  3. Austria Prof Helmut Mittermayer Belgium Prof Jan Verhaegen Bosnia Dr Selma Uzunovic-Kamberovic Bulgaria Prof Krassimir Metodiev Croatia Dr Arjana Tambic-Andrasevic Czech Republic Dr Pavla Urbaskova Denmark Dr Niels Frimodt-Møller Estonia Dr Paul Naaber Finland Dr Antti Nissinen France Dr Fred W. Goldstein Germany Prof Bernd Wiedemann Greece Prof Alkiviadis Vatopoulos Hungary Dr Éva Bán Iceland Dr Karl Gustaf Kristinsson Ireland Dr Martin Cormican Italy Prof Enrico Magliano Lithuania Prof Arvydsa Ambrozaitis Netherlands Prof John Degener Norway Dr Martin Steinbakk Poland Prof Waleria Hryniewicz Portugal Prof Jose Melo Cristino Romania no official representative Russia Prof Sergei Sidorenko Serbia Dr Lazar Ranin Slovak Republic Prof. Milan Niks Slovenia Dr Jana Kolman Spain Dr Francisco Soriano Sweden Dr Barbro Olsson-Liljequist Switzerland Prof Jaques Bille Turkey Dr Deniz Gür UK Prof Richard Wise Yugoslavia representative not confirmed Pharmaceutical Industry Representatives Prof. André Bryskier, Hoechst Marion Roussel Rep 2 not nominated Device Manufacturers Representatives Dr. Jean-Pierre Marcel, bioMérieux (appointed by STMA*) Ms. Maureen Mansfield, TREK (appointed by STMA*) Mr. Daniel Malait, Bio-Rad (appointed by STMA*) Mr. Ivo Steenackers, Becton-Dickison (appointed by STMA*) *Susceptibility Testing Manufacturers Association EUCAST general committee 2003

  4. EUCAST steering committee2002 - 2004 Gunnar Kahlmeter, chairman 2004 Derek Brown, Scientific secretary 2004 Alasdair MacGowan, BSAC (The UK) 2004 Fred Goldstein, CA-SFM (France) 2004 Johan W. Mouton, CRG (Netherlands) 2004 Arne Rodloff, DIN (Germany) 2004 Martin Steinbakk, NWGA (Norway) 2004 Anders Österlund, SRGA (Sweden) 2004 Pavla Urbaskova (Czech Republic), EUCAST rep 1 2003 Alkiviadis Vatopoulos (Greece), EUCAST rep 2 2003

  5. EUCAST steering committee 28th of January, 2003

  6. EUCAST appointments ESCMID appoints • chairman and scientific secretary every 3 years • National breakpoint committee seats on the steering committee every 3 years • 2 representatives from the EUCAST general committe from countries not represented on the steering committee through national breakpoint committee. European countries • appoint one representative each to serve for 2 years (new or confirmed appointments 2004) • can apply to the ESCMID board to be considered for a seat on the steering committee. To be eligible the country needs to have an active breakpoint committee or AST methodology committee with regular meetings (at least 4 per year are desirable for the BP-process).

  7. EUCAST websites • www.eucast.org – directly links to the EUCAST web-page on ESCMID site • ”www.eucast-steeringcommittee” – is used only by the steering committee (login with password needed) • ”www.wild-type-distributions” – new software – login for contributors of data; no login needed for access to data.

  8. September 2, 2001 September 11, 2001 October 3, 2001 October 4, 2001 November 2001 November 2001 December 2001 December 2001 January 2002 February 2002 April 2002 April 2002 2001/2002 May 2002 June 2003 July 2002 September 2002 October 2002 November 2002 November 2002 December 2002 8-15 January 2003 28 January 2003 27 February 2003 SRGA in Stockholm CRG in Bilthoven CA-SFM in Paris OEI (Orgainzation Epizotic International) in Paris EARSS meeting in Vienna RIVM and EARSS, Amsterdam BSAC in Birmingham ESCMID board meeting in Venice NEQAS in London NWGA in Oslo ESCMID board meeting in Italy ECCMID - EUCAST workshop/meeting Milan EARSS advisory board meetings in Bilthoven ECC in Paris IACMAC meeting in Moscow EARSS report 2001 - Amsterdam ICAAC in San Diego EUCAST reference database programme EARSS meeting in Bath Steering committee meeting in Shiphol Leading article on QA in JAC (DB and GK) NCCLS, Tampa, USA Steering committee meeting, Frankfurt ESCMID board meeting in Amsterdam Chairman´s activities since appointmentActivities in bold - paid by ESCMID

  9. EUCAST presented at/to • European Medicine´s Evaluation Agency (2002) • EARSS (2001, 2002) • NEQAS (2002) • Organisation Internationale Epizotic (2001) • NCCLS – bacteriology committe, antifungal committee, vet.committee (2003) • At international meetings: ECCMID (Milan 2002), ICAAC (San Diego 2002), FESCI (Paris 2002), IACMAC (2002), Drug Information Agency (2003) • At national meetings in Sweden, Denmark, The UK, Norway (2002), ….

  10. EUCAST invitations to co-operation • Medicine´s agencies (EMEA) • Breakpoint committees (NCCLS) • International Veterinary organisations • Drug industry (EFPIA) • Technical industry (STMA) • Surveillance (EARSS, NARMS etc) • Scientific organisations (ISC, FESCI) • EQA-programmes (EARSS, NEQAS)

  11. EMEA – discussions in London, dec 2003 Derek Brown, Alasdair MacGowan, G Kahlmeter (phone) EMEA will recognize EUCAST as the umbrella organisation for European national organisations provided: affirmation from national committees is obtained a non-industrial involvement on the financial side can be guaranteed affirmation from other interested parties, such as DG-SANCO, ISC/FESCI, FEMS, EFPIA, can be obtained - in progress!

  12. EUCAST is represented on • The national breakpoint committees • EARSS • NCCLS

  13. The EUCAST steering committee has defined… Clinical breakpoints S< X and R> Y mg/L New definitions of clinical breakpoints (S, I & R). Epidemiological cut-off values WT < Z mg/L Definitions of wild type and epidemiological cut-off values (WT and NWT).

  14. The EUCAST steering committee has… Closed all subcommittees except the subcommittee on antifungal susceptibility testing (EUCAST AFST) Decided on a common expression for S< and R> Decided on a common MIC microbroth dilution methodas reference gold standard. Decided on a process for setting breakpoints for new antibiotics (try outs: daptomycin, garenoxacin – both companies contacted) Decided on a process for harmonising breakpoints for existing antibiotics (fluoroquinolones successfully done, aminoglycosides, glycopeptides and linezolid is on) Proposed definitions for wild type bacteria and epidemiological cut-off values

  15. EUCAST at ECCMID in Glasgow Harmonization of quinolone breakpoints in Europe (12/5, 10-12) Chairpersons: Dr Martin Steinbakk (Norway) Dr Fred Goldstein (France) 1. Current breakpoints and the EUCAST approach to harmonization of breakpoints - Dr Derek Brown (UK) (10 min) 2. EMEA view on the harmonization of European breakpoints Dr Bo Aronsson (London, UK) (15 min) 3. Epidemiological cut off values based on wild type MIC distributions - Dr Gunnar Kahlmeter (Sweden) (15 min) 4. Pharmacodynamic approach and Monte Carlo simulation in establishing breakpoints Dr Johan W. Mouton (Netherlands) (15 min) 6. Tentative harmonized breakpoints for quinolones Dr Gunnar Kahlmeter (Växjö, Sweden) (10 min) 7. General discussion (30 min) Business meeting 12.15 - 13.30 Poster for the ESCMID poster corner

  16. EUCAST software: ”Antimicrobial wild type distributions” with EUCAST clinical breakpoints and epidemiological cut-off values The prototype is ready and paid for by ESCMID:6000 euro + VAT The bad news is – I need more for the final development: 3000 euro + VAT Approximately 750 distributions have been entered.

  17. Aggregated Ciprofloxacin/E.coli MIC-distributions from 6 separate data sources(national breakpoint committees, Antimicrobial resistance surveillance programs, EARSS, drugcompany data etc)

  18. EUCAST – expenditure 2002 • Chairman´s expenses 2002 : - NEQAS meeting in London, January 2002- ESCMID board meeting and ECCMID, Milan, Italy, April 2002- EUCAST reference database programme, autumn 2002 • EUCAST steering committee meetings- Shiphol, November 2002, 10 people

  19. EUCAST – expected expenditure 2003 • 4 scheduled steering committe meetings (10 – 15 000 Euro (?) per meeting):- January, Frankfurt- May, ECCMID, Glasgow- September- November • Soft ware: Wild type MIC- and Zone distributions – 3000 euro • Chairman´s travels – NCCLS, EMEA, ESCMID board: 5 – 10 000 Euro. • Newsletter has been dropped - contributions to go to the ESCMID Newsletter instead. • EU funding (application to go in March, 2003) • ESCMID industry contributions (?)

  20. Tentative new EUCAST definitions of S, I and R

More Related